Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talazoparib maintenance in platinum-sensitive triple-negative breast cancer
KCT0005671Phase 2Not yet recruiting
- Sponsor
- Pfizer
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of talazoparib in triple-negative breast cancer (TNBC), sponsored by Pfizer. Planned start Dec 2020; status: not yet recruiting.
02
Drugs
talazoparib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on KCT0005671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0005671.